These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18679829)

  • 1. Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines.
    Hall J; Gray S; A'Hern R; Shanley S; Watson M; Kash K; Croyle R; Eeles R
    Fam Cancer; 2009; 8(1):5-13. PubMed ID: 18679829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
    Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
    Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interest in BRCA1/2 testing in a primary care population.
    Armstrong K; Weber B; Ubel PA; Guerra C; Schwartz JS
    Prev Med; 2002 Jun; 34(6):590-5. PubMed ID: 12052018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.
    Green MJ; Peterson SK; Baker MW; Harper GR; Friedman LC; Rubinstein WS; Mauger DT
    JAMA; 2004 Jul; 292(4):442-52. PubMed ID: 15280342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
    Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
    J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
    Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
    BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer.
    Peters N; Domchek SM; Rose A; Polis R; Stopfer J; Armstrong K
    Genet Test; 2005; 9(1):48-53. PubMed ID: 15857187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
    Bluman LG; Rimer BK; Berry DA; Borstelmann N; Iglehart JD; Regan K; Schildkraut J; Winer EP
    J Clin Oncol; 1999 Mar; 17(3):1040-6. PubMed ID: 10071299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
    Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
    Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
    Evans DG; Lennard F; Pointon LJ; Ramus SJ; Gayther SA; Sodha N; Kwan-Lim GE; Leach MO; Warren R; Thompson D; Easton DF; Eeles R;
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2123-31. PubMed ID: 19567506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
    Dekanek EW; Thull DL; Massart M; Grubs RE; Rajkovic A; Mai PL
    J Genet Couns; 2020 Feb; 29(1):122-130. PubMed ID: 31729099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world health services utilisation and outcomes after
    Dossa F; Cusimano MC; Sutradhar R; Metcalfe K; Little T; Lerner-Ellis J; Eisen A; Meschino WS; Baxter NN
    BMJ Open; 2018 Sep; 8(9):e025317. PubMed ID: 30181190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
    Evans DG; Harkness E; Lalloo F; Howell A
    J Med Genet; 2014 Sep; 51(9):573-80. PubMed ID: 25053764
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.